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Abstract 
 
The mammalian target of rapamycin (mTOR) is a downstream mediator in the 
PI3K/AKT signaling pathway and plays an important role in cell proliferation on the 
molecular biology level. Rapamycin targets this pathway and blocks the downstream 
signaling elements. The development of rapamycin derivatives is an attractive target of 
anti-cancer therapy. 
 
 
 
Introduction 
 
 
The mammalian target of rapamycin (mTOR) is a kinase, in response to cell proliferation, 
growth, differentiation, and survival. mTOR is now recognized as a central regulator in a 
diverse array of vital cellular processes, including proliferation, growth, differentiation, 
and survival. It has been discovered that a role of mTOR signaling pathway dysregulation 
in tumourigenesis. mTOR and its upstream pathway were found to upregulate frequently 
in many human cancers. It is an existing discovery. mTOR and its upstream regulators 
indicate an attractively strategic target for anti-cancer therapy. 
 
The development of anti-cancer drugs related with PI3K/Akt pathway exhibits promising 
future. Several questions should be interesting in that how mTOR regulates protein 
synthesis, and eventually affects cell proliferation. What are the upstream elements that 
activate or inhibit the activity of mTOR, and their mechanisms? These aspects are major 
goal of the report. The main problems are that how mTOR regulates protein synthesis on 
molecular biology level and what is the activity of rapamycin as an anti-cancer drug. 
 
There are several regulators that affect mTOR have been indicated, the most studied one 
is the PI3K/Akt pathway. Its sequent regulation steps including PI3K/PTEN, AKT, 
TSC1/TSC2, and Rheb. They play positive or negative regulation function on the 
complex pathway. In addition, energy depletion and hypoxia and so on elements also 
could regulate mTOR, this report will not discuss them. 
 
Two of the most well-characterized mTOR downstream targets are 4E-BP1 and S6K1. 
Eukaryotic initiation factor 4E-binding protein (4E-BP1) binds to the surface of eIF4E, 
halts assembly of ribosome during translation initiation stage. The hyperphosphorylated 
4E-BP1 by mTOR prevents this interaction, make 4E-BP1 release from eIF4E. It’s one of 
mTOR positive regulation functions on protein synthesis. Another one is S6 (p70 S6) 
kinase 1 protein. The phosphorylated S6K1 by mTOR contributes to increased kinase 
activity and results in an increased phosphorylation level of 40S ribosomal S6 protein. In 
this way, mTOR enhances the translational capacity of cells. 
 
The most well known mTOR inhibitor is rapamycin which potently inhibits downstream 
signaling from mTOR. Rapamycin binds to the FK506-binding protein (FKBP12), and 
then the complex interacts with the FKBP12-rapamycin binding (FRB) domain of mTOR. 
 3
The resulting complex may alter the conformation of the multi-protein mTOR complexes, 
and impair mTOR activation of phosphorylation. Depend on this function, rapamycin 
exhibits the interesting attribute in the development of anti-cancer drug. In the end, report 
introduces three rapamycin derivatives CCI-779, RAD 001, and AP23573. They have 
already been under different human test phase. 
 
To solve the indicated problems, the report contains several parts. First, the description of 
TOR complexes in yeast and mammalian cells. Second, the major upstream and 
downstream targets of mTOR. For better understanding, the knowledge about 
phosphorylation and eukaryotic translation initiation is added in. The following section is 
a short part that introduces cancer mechanism and the relationship between cancer and 
mTOR. The final section is describing the rapamycin and its derivatives. 
 
In recent years, many research groups have been discovering mTOR functions and 
regulations that have formed from a single signaling pathway to a network. Actually, 
mTOR broadly relates to human pathophysiology, including cardiovascular diseases, 
autoimmune disorders, aging, and neuronal-related diseases. Reader could obtain basic 
background concerning mTOR on molecular biology level by reading this article. 
 
 
 4
1 TOR /mTOR and its associated protein 
 
 
1.1 TOR and its associated protein in yeast 
 
Yeast has two different TOR genes, termed TOR1 and TOR2. In Saccharomyces 
cerevisiae (baker's yeast), they encode proteins (Tor1p and Tor2p) with molecular masses 
of approximately 280KDa. Tor1p and Tor2p have 67% sequence identity, play a 
important role in translation initiation and cell progression in response to nutrient. (Qian 
Yang, 2007) Rapamycin inhibits both of these functions. An important function unique to 
Tor2p is that regulate the actin cytoskeleton during cell cycle progression. The 
cytoskeleton is cellular scaffolding, present in the cytoplasm. It is a dynamic structure 
that maintains cell shape such as flagella, has been known to protect the cell, and also 
plays important roles cellular division. Actin is a globular structural protein. It is one of 
the three major components of the cytoskeleton. Actin participates in many important 
cellular functions, including cell motility, cell division, cell signaling, and cell shape. 
 
There are the components of two distinct TOR-associated complexes in yeast. TOR 
complex 1 (TORC1) contains either Torp1 or Torp2, together with Kontroller of growth 1 
(Kog1p) and Lethal with sec thirteen (Lst8p). TORC1 modulates translation initiation and 
represses the transcription of specific genes that are induced by nutrient starvation. After 
rapamycin treatment, it has been found that TORC1 is a rapamycin-sensitive complex; 
the functions of TORC1 are inhibited by the rapamycin-FKBP12 complex. TOR complex 
2 (TORC2) contains Tor2p, Avo1p (Adheres voraciously to Tor2), Avo2p, Avo3p, and 
Lst8p. TORC2 mediates the reorganization of the actin cytoskeleton. However, compared 
with TORC1, the rapamycin-FKBP12 complex doesn’t bind to or inhibit TORC2 
(rapamycin-insensitive complex). (Qian Yang, 2007) 
 
1.2 mTOR and its associated protein in mammalian cells 
 
mTOR complex contains two distinct branches, mTOR complex 1 and mTOR complex 2. 
We discuss them respectively in following parts. 
 
1.2.1 mTOR complex 1 
 
Mammals have a single TOR gene, termed mTOR. The functional mTOR complex 1 
(mTORC1) contains at least two essential subunits Raptor and mLst8/Gβ L . (Figure 1 
shows several components that belong to mTORC1 or mTORC2 respectively). Raptor 
(regulatory associated protein of mTOR) is a mammalian counterpart of Kog1p in yeast, 
and mLst8/Gβ L is a mammalian ortholog of the yeast Lst8p. Raptor is a 150kDa protein, 
including Raptor N-terminal conserved domain (RNC), three HEAT repeats, and seven 
WD40 repeats. mLst8/Gβ L is composed of seven WD40 repeats. (Qian Yang, 2007) 
Both Raptor and mLst8 play important roles in mTOR regulation. 
 
Raptor is an essential and presumably non-enzymatic subunit of mTORC1. (Hara K, 
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2002) When Raptor is present in the mTOR complex, mTOR can efficiently 
phosphorylate both S6K and 4EBP1, two well-known targets of mTOR. When Raptor is 
absent in the mTOR complex, mTOR shows decreased ability to phosphorylate its 
substrates. Raptor demonstrates a positive effect on mTOR activity. In mammalian cells, 
knock down of Raptor expression causes a decrease in cell size, just as in cells in which 
mTOR expression was knocked down (Kim, D. H., 2002), indicates the Raptor and 
mTOR complex is critical for mTOR function. Raptor serves as a scaffolding protein to 
bridge the interaction between mTOR and its substrates. S6K contains a TOR signaling 
motif (TOS motif) mutation on it disrupt the phosphorylation of S6K by mTOR. This 
effect is also found on 4E-BP1. Mutation of TOS motif drops both S6K and 4E-BP1 
binding to Raptor, and such mutants relate with a low rate of phosphorylation by mTOR. 
(Schalm, S. S. 2003) (Choi, K. M, 2003) Raptor plays a role as an adaptor to recruit 
substrates to be phosphorylated by mTOR. 
 
In addition to TOS motif, the 4 amino acids RAIP motif in 4E-BP1 is also important for 
mTOR-dependant phosphorylation of 4E-BP1. Mutation on RAIP motif disrupts the 
binding of 4E-BP1 with Raptor in vivo. However, 4E-BP1 only contains an intact RAIP 
motif is not sufficient to bind Raptor. (Choi, K. M, 2003) (Beugnet, A. 2003) Thereby, 
suggesting that the RAIP motif is necessary but not sufficient for 4E-BP1 to engage with 
Raptor. 
 
 
 
 
Figure 1. mTOR complex components. HEAT: a protein-protein interaction structure of two tandem 
anti-parallel a-helices found in huntingtin, elongation factor 3, PR65/A and TOR; FAT: a domain 
structure shared by FRAP, ATM and TRRAP, all of which are PIKK family members; FRB: 
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FKBP12/rapamycin binding domain; FATC: FAT C-terminus; RNC: Raptor N-terminal conserved 
domain; WD40: about 40 amino acids with conserved W and D forming four anti-parallel beta strands. 
(Qian Yang, 2007) 
 
mLst8 is another essential component of the functional mTORC1. mLst8 interacts with 
mTOR kinase domain, and mLst8 mutants show decreased ability to activate mTOR.. 
Knock out of mLst8 expression inhibits the phosphorylation of S6K, also result in a 
decrease in protein synthesis. The phenotype is similar to the effect of knock down of 
either mTOR or Raptor. Overexpression of mLst8 stabilizes the interaction between 
mTOR and Raptor, and enhances mTOR kinase activity. (Kim, D. H. 2003) These 
observations led to the conclusion that mLst8 appears to play a positive role in mTOR 
signaling. Like Raptor, it’s is critical for targeting the mTOR to its substrates. However, 
in contrast to Raptor, mLst8 does not directly interact with mTOR substrates or regulate 
the mTOR protein level. (Kim, D. H. 2003) 
 
1.2.2 mTOR complex 2 
 
Rictor is a mammalian counterpart of Avo3p in yeast. Like yeast TORC2, the 
Rictor-mTOR complex does not possess Raptor, and therefore is referred to as 
mammalian TORC2 (mTORC2). The Rictor-mTOR complex plays an important role in 
the regulation of cytoskeleton organization in mammalian cells. It’s similar to the yeast 
TORC2. The Rictor and mTOR complex is resistant to rapamycin under phosphate-rich 
conditions. (Sarbassov dos, D. 2004) However, the precise mechanism of mTORC2 
regulation has not been determined. The crucial role of Rictor in the cytoskeleton may 
explain the previous observation that rapamycin fails to disrupt TORC2 regulation of 
cytoskeleton in yeast.  
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2 Major downstream targets of mTOR 
 
mTOR regulates protein synthesis through the phosphorylation and inactivation of the 
repressor of mRNA translation, eukaryotic initiation factor 4E-binding protein (4E-BP1), 
and the phosphorylation and activation of S6 kinase (S6K1). These effects eventually 
result in cell proliferation, inhibiting of these effects could be potential treatment for 
cancer diseases. Thereby, finding out the relative mechanisms are required for the 
development of anti-cancer drug. 
 
2.1 Phosphorylation 
 
Phosphorylation is the addition of a phosphate (PO4) group to a protein molecule or a 
small molecule, Phosphorylation can occur in both prokaryotic and eukaryotic organisms. 
Dephosphorylation is its reverse process. These processes involve two kinds of enzymes, 
kinases catalyze phosphorylation, and phosphatases catalyze dephosphorylation. 
Phosphorylation and dephosphorylation can turn on or turn off specific protein functions, 
act as important regulation mechanism. Phosphorylation and dephosphorylation change 
conformation of proteins, cause their states from activated to deactivated, or from 
deactivated to activated. A series of Phosphorylation/dephosphorylation occur in mTOR 
related activities, discussed in following parts. 
 
There are thousands of different phosphorylation sites in a given cell. Phosphorylation 
usually occurs on the basic amino acid residues serine, threonine, and tyrosine (Serine is 
the most common, followed by threonine. Tyrosine phosphorylation is relatively rare) in 
eukaryotic proteins, and on histidine, arginine, lysine residues in prokaryotic proteins.  
 
The network of phosphorylation could be very complex. Elucidating signaling pathway 
phosphorylation events is quite difficult. For instance, in a cellular signaling pathway, a 
protein A phosphorylates protein B, and B phosphorylates C. However, in another 
signaling pathway, protein D could phosphorylates B, or dephosphorylates B.  
 
2.2 Brief eukaryotic translation initiation 
 
Major targets of mTOR focus on translation stage. The translation of the mRNA 
nucleotide sequence into protein takes place in the ribosome in where individual amino 
acids added to polypeptide chains. The tRNA molecules carry amino acids which are 
used for protein synthesis to the ribosome by recognizing complementary codons 
(particular three nucleotides sequence) in the mRNA. The information conserved in 
mRNA nucleotides sequence is translates to proteins. 
 
In eucaryotes, to initiate translation the initiator tRNA attached to methionine binds to the 
small subunit of ribosome with the proteins called eucaryotic initiation factors, or eIFs. 
And then the small ribosomal subunit binds to the 5′ end cap (m7G-cap structure) of a 
post-transcribed mRNA molecule (Figure 2 and Figure 3). One of the eIFs, called eIF4E 
recognizes and directly binds to 5’ cap of the mRNA. The small ribosomal subunit 
complex then moves forward (5′ to 3′) along the mRNA. When it reaches AUG (the 
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translation start codon) that is recognized by initiator tRNA molecule, a large ribosomal 
subunit binds to complete the ribosome and begin the elongation phase of translation.  
 
The eIF4E connects two other proteins, the large scaffolding protein eIF4G and the RNA 
helicase eIF4A. They act as a bridge to connect eIF4E and the complex that is small 
ribosomal subunit and other eIFs. 
 
eIF4A
eIF4E 
 
 
Figure 2 Ribosome initiation complex at the 5’ end cap of an mRNA. Eucaryotic initiation factor 4E 
(eIF4E) recognizes and directly binds to 5’ cap (m7G-cap structure) of the mRNA. Other eIFs and 40S 
ribosomal subunit are guided to 5’ cap. The large scaffolding protein eIF4G and the RNA helicase 
eIF4A act as a bridge to connect eIF4E and the complex that is formed by small ribosomal subunit and 
other eIFs. The small ribosomal subunit complex then moves forward (5′ to 3′) along the mRNA. 
When it reaches AUG (the translation start codon) that is recognized by initiator tRNA molecule 
which attached on 40S subunit, a large ribosomal subunit binds to complete the ribosome and begin 
the elongation phase of translation. (Nissim Hay. 2004) 
 
 
 9
Figure 3. The initiation and elongation phases of translation in eukaryotes. The 5’ cap binding protein 
eIF4E is sequestered by hypophosphorylated 4E-BPs, because hypophosphorylated 4E-BPs possess 
high affinity than 5’ cap. The 4E-BPs are hyperphosphorylated to release eIF4E by mTOR (described 
in next section), such that it can interact with the scaffolding protein, eIF4G. In conjunction with the 
RNA helicase eIF4A and the cofactor eIF4B, 5’ secondary structure is melted. A small ribosomal 
subunit is then recruited to a single-stranded mRNA through an interaction between eIF4G and eIF3. 
The small ribosomal subunit with eIF2, GTP, and Met-tRNAi (initiator tRNA attached with 
methionine) scans the mRNA in a 5’ to 3’ direction until an AUG start codon is encountered. At this 
point, initiation factors are released, and the large ribosomal subunit and elongation factors are 
recruited. (Brian Raught, 2001) 
 
 
2.3 mTOR downstream targets  
 
Several downstream targets of mTOR have been found by studying rapamycin-induced 
cellular responses, including eukaryotic initiation factor 4E-binding protein (4E-BP1), 
ribosomal S6 kinase 1 (S6K1), protein phosphatase 2A (PP2A), insulin receptor substrate 
1 (IRS-1) etc. mTOR regulates these targets that affect protein synthesis to play the roles 
of mTOR in the control of cell growth and proliferation, as well as its relevance to cancer. 
This section pays more attention on the discussion of 4E-BP1 and S6K1, two of the most 
well-characterized mTOR targets. 
 
2.3.1 4E-BPs 
 
Eukaryotic initiation factor 4E-binding proteins (4E-BPs) include three low weight 
proteins, 4E-BP1, 4E-BP2 and 4E-BP3, encoded by three different genes. The three 
members repress mammalian translation via inhibition of ribosome assembly.  
 
4E-BPs binds to the surface of eIF4E to inhibit it interact with eIF4G, further halts 
ribosome binding. 4E-BPs compete the binding site on eIF4E with eIF4G, only one of 
them could possess of the overlapping binding site. The hypophosphorylated 4E-BPs 
have high affinity to bind with eIF4E, but the hyperphosphorylated 4E-BPs prevent this 
interaction. Once 4E-BPs bind to eIF4E, it will block the eukaryotic translation initiation. 
(Figure 4) 
 
 
 
eIF4E 
Figure 4 4E-BPs regulate the interaction between eIF4E and eIF4G. 4E-BPs compete the binding site 
on eIF4E with eIF4G, only one of them could possess of the overlapping binding site. The 
hypophosphorylated 4E-BPs have high affinity to bind with eIF4E, but the hyperphosphorylated 
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4E-BPs prevent this interaction. The 4E-BP- eIF4E complex blocks the eukaryotic translation 
initiation. (Nissim Hay. 2004) 
 
4E-BP1 is a well-characterized TOR target. Hypophosphorylated 4E-BP1 acts as a translation 
repressor by binding and inhibiting the interaction between 5’ end cap and eukaryotic translation 
initiation factor 4E (eIF4E), which recognizes the 5’ end cap of the majority of eukaryotic mRNAs. 
Phosphorylation of 4E-BP1 by mTOR results in the dissociation of 4E-BP1 from eIF4E. Thereby, 
rescuing the inhibitory effect of 4E-BP1 on eIF4E-dependtent translation initiation. Rapamycin 
reduces the phosphorylation of 4E-BP1 and partially prevent its dissociation from eIF4E. 
 
 
The three 4E-BPs have different phosphorylation sites. Seven phosphorylation sites have 
been observed in 4E-BP1, (Thr37, Thr 46, Ser 65, Thr 70, Ser 83, Ser 101, and Ser 112). 
Ser101 and Ser112 are conserved only in 4E-BP1, the other phosphorylation sites exist 
among all 4E-BPs. Most of 4E-BPs studies were depended on 4E-BP1, so the discussion 
of the mTOR effects on 4E-BPs will focus on the 4E-BP1 which is also known as 
PHAS-1 (phosphorylated heat- and acid-stable protein 1). 
 
mTOR phosphorylate two priming sites (Thr 37 and Thr 46) in mammalian 4E-BP1 in 
vitro.( Figure 5) And then require that phosphorylation of Thr 70 followed by Ser 65. 
Eventually, these phosphorylations make 4E-BP1 to release from eIF4E. Therefore, the 
mTOR could enhance the level of translation initiation. In contrast, treatment with 
rapamycin results in the dephosphorylation of 4E-BP1, increase in 4E-BP1- eIF4E 
binding, decrease in the translation of mRNAs. (Brunn GJ, 1997) (Gingras, A. 2001) 
 
In addition, overexpression of rapamycin-insensitive mTOR results in 4E-BP1 
phosphorylation even in the presence of rapamycin. Phosphorylation sites of Thr70 and 
Ser65 are more sensitive to rapamycin treatment than other sites. (Brunn GJ, 1997) 
 
 
 
Figure 5 Hierarchical phosphorylation of 4E-BP1. (Nissim Hay. 2004) Thr 37 and Thr 46 are the 
primary phosphorylation sites on 4E-BP1, the subsequent phosphorylations occur on Thr 70 and Ser 
65. The hierarchical phosphorylations of 4E-BP1 cause 4E-BP1 release from eIF4E. 
 
However, several studies reveal that Ser 65 phosphorylation is insufficient for dissociate 
the 4E-BP1-eIF4E complex; it may involve the other phosphorylation sites. (Karim, M.M. 
2001) 
 
 
2.3.2 S6 kinase 
 
5’ TOP (5’ terminal oligopyrimidine tract) mRNAs contain a short (4-14 nucleotides) 
polypyrimidine tract and immediately adjacent to their 5’ end. These TOP-containing 
 11
mRNAs often code for components of the translational apparatus, most notably, including 
ribosomal proteins, other translational regulators, and elongation factors. (Meyuhas and 
Hornstein, 2000) The ribosomal proteins, translational regulators and the elongation 
factors are required for translation initiation and translation elongation respectively.  
 
S6 (p70 S6) kinase proteins are parts of the mechanism of translation, contain S6K1 and 
S6K2 in mammalian cells, are direct targets of mTOR. S6K1 was discovered earlier than 
S6K2, so it has been more used to research phosphorylation substrate and cell growth 
effect. A number of evidences indicate that activated S6K1 affect on cell growth control 
through increased a family of 5’ TOP mRNAs translation. 
 
mTOR activates S6K1 by phosphorylation. The phosphorylated S6K1 contributes to 
increased kinase activity and results in an elevated phosphorylation of 40S ribosomal S6 
protein. (Proud, C. G. 2002.) The phosphorylation of S6K by TOR involves multiple sites. 
Two of them, Thr389 and Ser371 are the major mTOR phosphorylation sites (Burnett. 
1998) and essential for S6K activation (Pearson. 1995). 
 
The phosphorylated S6K1 phosphorylates the 40S ribosomal protein S6. The subsequent 
phosphorylation steps lead to the recruitment of the 40S ribosomal subunit into actively 
translating form. In this way, S6K enhances the translational capacity of cells.  
 
Rapamycin was shown to inhibit phosphorylation on these sites. (Han, J. W. 1995) In 
addition, deletion or mutation of five amino acids residues (Phe-Asp-Ile-Asp-Ile, named 
as TOS (TOR Signaling)) that located close to the N terminal of S6K significantly blocks 
activation of S6K. (Schalm, S. S. 2002) Similarly, deletion or mutation the N terminal 
sites of S6K drop sensitive to rapamycin treatment. (Weng, Q. P. 1995) So suggesting 
that these five sites are critical for mTOR-mediated activation of S6K. 
 
In summary, mTOR exhibits the ability to phosphorylate 4E-BP1 and S6K1. The 
phosphorylated 4E-BP1 dissociates from eIF4E, allowing the eukaryotic translation 
initiation progresses to next step. The phosphorylated S6K1 plays an important role for 
assembly of 40S ribosomal subunit. Ultimately, both of two mTOR downstream targets 
promote cell proliferation. Rapamycin interferes phosphorylation on 4E-BP1 and S6K1, 
contributes to its antiproliferative actions. The question how rapamycin performs the 
actions will be discussed in the section about rapamycin. 
 
2.3.4 eIF4B 
 
eIF4B may be an important mediator of some of the effects of S6Ks on translation and 
cell growth. One of the phosphorylation sites (Ser 422) in eIF4B is specifically 
phosphorylated by S6K1/S6K2. (Raught. 2004) 
 
eIF4B is ubiquitous RNA-binding protein that stimulates the activity of eIF4A (RNA 
helicase) which thought to unwind mRNA 5’ secondary structure. It has been suggested 
that increased phosphorylation enhances eIF4B activity and the translation of mRNAs 
contains some degree of secondary structure (Manzella. 1991). So eIF4B plays a 
 12
regulation role in translation of mRNA. Concerning S6K, eIF4B is an indirect target of 
mTOR.  
 
2.3.5 eIF4G 
 
eIF4G is phosphoprotein, acts an important element in the assembly of the ribosome 
initiation complex. All eukaryotes have two related eIF4G proteins, eIF4GI and eIF4GII. 
They consist of three functional and structural domains which interact with different 
initiation factors. The extracellular stimuli, including serum, insulin and growth factor 
that promote cell growth, increase the phosphorylation of eIF4GI. eIF4GI has two kinds 
of phosphorylation sites, one phosphorylation site was mapped on the N-terminal third of 
the protein that contains Ser314. (Byrd. 2002) However, the Ser314 phosphorylation 
condition is still unknown. Other phosphorylation sites were mapped on the hinge region 
between the middle and C-terminal domains that contain Ser 1148, Ser 1188 and Ser 
1232. These phosphorylation sites are sensitive to mTOR inhibitors. (Raught. 2000a) The 
phosphorylation sites of eIF4GII are not clear. The biochemical activity of eIF4Gs 
phosphorylation by mTOR has not been determined yet. Suggestion the eIF4Gs 
phosphorylation creates a conformational change in the protein that affects its activity. 
mTOR promotes the ability of eIF4Gs recruit ribosome initiators, rapamycin blocks it. 
(Raught. 2000a) 
 
2.3.6 eEF2 
 
In addition to the S6Ks and 4E-BP1, both of which modulate translation initiation, 
mTOR signaling also regulates the translation elongation process through the 
phosphorylation of eukaryotic elongation factor 2 (eEF2). eEF2 is a GTP binding protein 
that mediates the translocation step of elongation. When phosphorylated at Thr56, eEF2 
by mTOR loses its ability to bind to ribosomes and is thus inactivated. This effect is 
blocked by rapamycin. This appears to involve decreases in the activity of a specific 
enzyme called eEF2 kinase. The eEF2 kinase acts on eEF2. The ability of insulin to 
decrease eEF2 kinase activity is blocked by rapamycin, implying that this effect is also 
mediated through mTOR. (Browne. 2004) 
 
2.4 mTOR targets involved in ribosome biogenesis 
 
Cells must control the production and abundance of the ribosomes to regulate cell growth 
and proliferation on the basis of cellular level. Ribosome biogenesis involves more than 
100 genes and all three RNA polymerases (Pol I, II, and III). RNA polymerase I (Pol I) 
transcribes rRNA genes, RNA polymerase II (Pol II) transcribes ribosomal protein genes, 
RNA polymerase III (Pol III) transcribes tRNA and 5S genes. In both yeast and mammals, 
TOR regulates ribosome biogenesis at multiple levels, including transcription, rRNA 
processing, and translation. mTOR regulates ribosome translation involves the action of 
S6K and S6 (see the previous section). 
 
TOR is also a conserved regulator of rDNA transcription. rDNA is a kind of DNA that 
specifically codes for components of the ribosome. For instance, the activity of TIF-IA 
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(an essential initiation factor associated with the initiation-competent form of Pol I) is 
also regulated indirectly by mTOR. The mTOR-dependent kinase S6K mediates the 
phosphorylation of Ser44 on TIF-IA. Rapamycin inhibits TIF-IA activity by decreasing 
Ser44 phosphorylation. (Mayer. 2004) In addition, TOR regulates ribosome biogenesis by 
modulating rRNA processing, including processing of the 35S precursor rRNA (Albig. 
2001) (Powers. 1999) This report focuses on the regulation functions on translation by 
mTOR, so no going to discuss more details about above topics. 
 
2.5 mTOR translational control, cell growth, and proliferation 
 
In mammalian translation initiation, the rate-limiting step is the binding of the ribosome 
to mRNA. Almost all factors involved in recruiting the ribosome, including eIF4E, eIF4B, 
eIF4G, are phosphoproteins. Their phosphorylation states are directly relative to 
translation and consequent growth rates of the cell. Furthermore, the repressor proteins 
4E-BPs are phosphorylated under the same circumstances. So in response to extracellular 
stimuli, increased phosphorylations of these factors relate with increased mRNAs 
translation and accelerated cell growth and proliferation. The mTOR pathway mediates 
the phosphorylation of all of these factors, except for eIF4E.  
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3 The mammalian target of rapamycin 
 
The mammalian target of rapamycin (mTOR) is a kinase in response to cell proliferation 
and cell survival signaling. Its activation affects cell cycle forces from G1 to S phase. The 
signaling and the cell cycle are discussed in the chapter of cancer. 
 
mTOR is also known as FRAP (FKBP12-rapamycin associated protein), RAFT 
(rapamycin and FKBP target), RAPT (rapamycin target protein), and SEP (sirolimus 
effector protein). It’s a large, polypeptide, serine/threonine-specific kinase of 289 KDa. 
mTOR can interact with the FKBP12 (FK506-binding protein, molecular mass of 
12kDa)-rapamycin complex, as the target of FKBP12-rapamycin complex.  
 
3.1 Structure of mTOR 
 
mTOR is high molecular-weight protein which contain several distinct domains, 
including 2549 amino acids and comprise several conserved structural domains (Figure 6). 
Its structure seems to be highly conserved from yeast to mammalian cells. Human, mouse 
and rat mTOR proteins are identified 95% similarity at amino acid level. (Nissim Hay. 
2004) 
 
 
 
Figure 6 the primary structure of mTOR. (Nissim Hay. 2004) From N terminal to C terminal, HEAT 
(Huntignton, EF3, A subunit of PP2A, TOR) repeats domain. FAT (FRAP, ATM, TRAP) domain. 
FRB domain (FKBP12-rapamycin binding), the small protein domain enable to bind 
FKBP12-rapamycin complex. Kinase domain, it’s similar with the catalytic domain of 
phosphatidylinositol 3-kinase (PI3K). NRD domain is supposed to be the negative regulatory domain. 
On C terminal, FATC domain has been proposed that interacts with FAT domain to yield a 
configuration that exposes the catalytic domain. 
 
There are 20 tandem HEAT (Huntignton, EF3, A subunit of PP2A, TOR) repeats on the 
N terminus. Each one consists of two α helices of about 40 amino acids, each HEAT has 
a specific pattern of hydrophobic and hydrophilic residues.  
 
The C terminal half of mTOR contains the kinase domain, the sequence is similar with 
the catalytic domain of phosphatidylinositol 3-kinase (PI3K). N terminal to the kinase 
domain, the mTOR contains a potential regulatory region of approximately 100 amino 
acids, the FRB domain (FKBP12-rapamycin binding), the small protein domain enable to 
bind FKBP12-rapamycin complex, some studies reveal Ser 1972/1975, Trp 2042 and Phe 
2049 residues are important for the interaction of mTOR with the FKBP12-rapamycin 
complex. Rapamycin binds to mTOR through FKB12. FKB12 possesses a hydrophobic 
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binding pocket, FRB domain also possesses a hydrophobic pocket. Thus contact FKB12 
and mTOR together. This mechanism may explain why rapamycin cannot interact with 
mTOR by itself, in despite of FKBP12-rapamycin complex inhibits mTOR function is 
still unknown.  
 
In addition, mTOR contain a relatively large FAT (FRAP, ATM, TRAP) domain, 
spanning approximately 500 amino acids N terminal to the FRB and catalytic domain in 
mTOR, and FATC domain. Both of them are PIK-related kinase. The FATC domain is 
important for mTOR activity. It has been proposed that the FAT and FATC interact to 
yield a configuration that exposes the catalytic domain. mTOR also contains a supposed 
negative regulatory domain (NRD) between the catalytic and FATC domains. 
 
3.2 The regulation of mTOR activity 
 
There are several factors regulate mTOR activity, including nutrients, energy metabolism, 
and growth factors. The term growth factor refers to a naturally occurring protein capable 
of stimulating cellular proliferation and cellular differentiation. Growth factors are 
important for regulating a variety of cellular processes. 
 
3.2.1 Control by nutrients 
 
TORs (target of rapamycin) were first discovered and cloned from yeast gene. There are 
five protein complexes interact with TOR1 and TOR2. AVO1, AVO2, and AVO3 
interact only with yeast TOR2. The integrity of these complexes doesn’t appear to be 
affected by either rapamycin or nutrient starvation. LST8 and KOG1 (kontroller of 
growth-1) interact independently with either yeast TOR1 or yeast TOR2, and they were 
suggested to be positive regulator of TOR. TORs in mammalian are called mTOR. The 
mammalian ortholog of KOG1 is called Raptor (regulatory associated protein of TOR). 
All Raptor homologs contain a unique conserved domain in the N terminal half, followed 
by three HEAT repeats, and seven WD-40 repeats in the C terminal half. The HEAT 
repeats in the N terminal domain of mTOR are required to interact efficiently with Raptor. 
However, the C terminal half of mTOR also bind weakly to Raptor. Multiple mutations in 
N terminal region and the HEAT repeats in Raptor affect the binding between Raptor and 
mTOR reveals that Raptor may interact with mTOR through multiple contact points (Kim, 
D.H. 2002). Normally Raptor is a positive regulator of mTOR. 
 
Raptor conserves 150-kDa protein in its C terminal that binds to the downstream targets 
of mTOR, S6K1, and 4E-BP1. It’s necessary for the phosphorylation of 4E-BP1 by 
mTOR and for the efficient phosphorylation of S6K1. TOS (5 amino acids, TOR 
signaling) mediates the interaction of Raptor with 4E-BP1 and S6K1. TORS possesses in 
the N terminal of 4E-BP1 and S6K1. Rapamycin disrupts the mTOR-Raptor interaction, 
so prevents the ability of mTOR to phosphorylate 4E-BP1 and S6K1. 
 
The 36 kDa mLST8 (the mammalian ortholog of LST8, previously known as GβL, G 
protein β-subunit-like protein) also acts as positive regulator in mTOR activation by 
nutrients. It contains seven WD-40 repeats, interacts specifically with the kinase domain 
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of mTOR. mLST8/GβL, Raptor, and mTOR comprise a nutrient-sensitive mTOR 
complex. mLST8/GβL regulates the stability of Raptor-mTOR association under distinct 
nutrient conditions. However, the mLST8/GβL-mTOR-Raptor complex doesn’t explain 
the regulation mechanism by which mTOR senses nutrient availability. 
 
Nutrient condition such as amino acid availability affects the ability of mTOR to interact 
with and phosphorylate its substrates. (Figure 7) 
 
 
 
Figure 7 nutrient conditions affect the ability of mTOR to interact with and phosphorylate its 
substrates. In the absence of nutrients, The C terminal half of mTOR weakly binds to Raptor, prevent 
that mTOR binds to its substrates. In the presence of nutrients, mTOR (or an associated kinase) enable 
to access its targets, 4E-BP1 or S6K1, which bind to Raptor. (Nissim Hay. 2004) 
 
 
When amino acids absent in nutrient condition. The C terminal half of mTOR weakly 
binds to Raptor. The mTOR-mLST8-Raptor complex prevent that mTOR binds to its 
substrates and/or mTOR (or mTOR associated kinase) accesses to the substrates. 
 
When amino acids present in nutrient condition, the conformation of 
mTOR-mLST8-Raptor complex is changed, the change promotes efficient interaction 
between Raptor and mTOR substrates and/or accessibility of mTOR with its substrates 
and with its associated kinases. The conformational change disrupts Raptor mLST8 
interaction and than mTOR (or an associated kinase) enable to access its targets, 4E-BP1 
or S6K1, which bind to Raptor. 
 
 
3.2.2 Control by growth factor 
 
Several growth factors regulate the pathways of mTOR activation, including PI3K/PTEN, 
AKT, TSC1/TSC2, and Rheb. 
 
3.2.2.1 PI3K/PTEN 
 
Insulin and other growth factors increase the phosphorylation of S6K1 and 4E-BP1 in a 
rapamycin-sensitive manner. The mutations in the PDGF (platelet-derived growth factor 
is one of the growth factors) receptor interfere that recruitment and activation PI3K 
(phosphoinositide-3-OH kinase), also inhibit the phosphorylation of S6K1 by PDGF 
(Chung. 1994). The mutations in IRS-1 (insulin receptor substrate 1, only activates PI3K) 
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promote phosphorylation of 4E-BP1 induced by insulin. (Chung. 1994)(Mendez. 1996) 
These evidences confirm that PI3K mediates the growth factor induced activation of 
mTOR. PI3k is a positive regulator of mTOR, because much lower concentration of 
wortmanin (pharmacological inhibitor) is required to inhibit mTOR activity, using 
4E-BP1 and S6K1 phosphorylation as readouts. In addition, overexpression of 
dominant-negative forms of p85 (the regulatory subunit of PI3K) inhibits insulin-induced 
phosphorylation of S6K1. (Sharma, P.M 1998)(Ueki, K. 2000) The overexpression of 
p110, activated catalytic subunit of PI3K, induces 4E-BP1 phosphorylation. (Gingras, A. 
1998) 
 
PTEN ( phosphatase and tensin homolog on chromosome 10 ) is a phosphatidylinositol-3 
phosphatase that counteracts PI3K activity by dephosphorylating 
phosphatidylinositol-3,4-bisphosphate (PIP2) and phosphatidylinositol-3,4,5-triphosphate 
(PIP3) that are generated by PI3K (Fig. 4). 
 
These results were confirmed by the observations that PTEN-deficient cells have high 
levels of 4E-BP1 and S6K1 phosphorylation.  
 
 
3.2.2.2 Akt 
 
Akt (Serine/threonine protein kinase, also known as PKB, protein kinase B) is a 
downstream effector of PI3K. The different genes encode three separate Akt proteins in 
mammalian cells. The PDK1 (3-phosphoinositide-dependent kinase-1) and another still 
unknown PI3K-dependent kinase phosphorylate Akt. The full activation of Akt requires 
both of the phosphorylation events.  
 
Akt is a positive regulator of mTOR. The study of mice cells, lacking Akt1 and Akt2 
(two of three Akt proteins), reveals the Akt function as an upstream effector of mTOR in 
mammalian cells. S6K1 and 4E-BP1 are downstream targets of mTOR, mTOR activates 
S6K1 and inhibits 4E-BP1. The functions of mTOR indicate that the high concentration 
of mTOR increase the phosphorylation level of S6K1, and decrease the phosphorylation 
level of 4E-BP1. The interesting result is that when lack Akt1 and Akt2 in mice cells, 
S6K1 phosphorylation is not decreased as remarkably as increased 4E-BP1 
phosphorylation in cells (Peng, X.D. 2003). So suggest the activity of Akt sufficiently 
promotes S6K1 phosphorylation, and 4E-BP1 phosphorylation is more dependent than 
S6K1 phosphorylation on Akt activity. 
 
 
3.2.2.3 TSC1/TSC2 
 
The discovery of TSC1 (also known as hamartin, encoded by the tuberous sclerosis 
complex 1 (TSC1) gene) and TSC2 (also known as tuberin, encoded by tuberous sclerosis 
complex 2 (TSC2) gene) can explain how growth factors and Akt regulate mTOR activity. 
These proteins act as tumour growth suppressors, agents that regulate cell proliferation 
and differentiation. Thus, mutations at the TSC1 and TSC2 loci result in a loss of control 
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of cell growth and cell division, and therefore a predisposition potentially could form 
tumors. TSC1 and TSC2 interact through their N terminal, perform relative functions. 
 
TSC1 and TSC2 interact through their N termini and appear to function as a heterodimer. 
The overexpression of both TSC1 and TSC2 decreases phosphorylation of S6K1 and 
4E-BP1. When lacking a functional TSC1 or TSC2, S6K is highly phosphorylated in 
mammalian cells. So the TSC1/TES2 heterodimer is an upstream negative regulator of 
mTOR (Gao, X. 2002). Further more a mutant of TSC2 with Akt-phosphorylated residues 
acts as a dominant inhibitor of mTOR via blocking its activation in response to growth 
factors (Inoki, K. 2002). These evidences strongly support that Akt activates mTOR 
through the phosphorylation and inactivation of TSC2 (Figure 8). However, the precise 
mechanism of Akt phosphorylation affects the TSC1/TSC2 function is still unknown. 
 
 
 
 
 
Figure 8. The growth factors regulate mTOR activation by the PI3K/Akt pathway. (+) Activation; (−) 
inhibition. The PI3K/Akt signaling pathway regulates the activity of mTOR regulation. Akt 
phosphorylates and inhibits TSC2. The subsequent factor is the activation of Rheb that activates 
mTOR by a still unknown mechanism. (More details are described in the text) (Nissim Hay. 2004) 
 
 
3.2.2.4 Rhed 
 
Guanosine-5'-triphosphate (GTP) is a purine nucleotide. Its structure is similar to that of 
the guanine nucleotide, the only difference being that there are two extra phosphate 
groups added on. GTP is essential to signal transduction, particularly with G-proteins, 
where it is converted to GDP (guanosine diphosphate) through the action of GTPases. 
GTP is also involved in energy transfer within the cell. For instance, a GTP molecule is 
generated by one of the enzymes in the citric acid cycle in mammals. This is tantamount 
to the generation of one molecule of ATP since GTP is readily converted to ATP. 
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GTPases are a large family of hydrolase enzymes that can bind and hydrolyze GTP. All 
regulatory GTPases have a common mechanism that enables them to switch a signal 
transduction chain on and off. The switch function is performed by the unidirectional 
change of the GTPase from the active (GTP-bound form) to the inactive, GTP-bound 
form is synthesized by hydrolysis of the GTP through intrinsic GTPase-activity, 
effectively switches the GTPase off. This reaction is initiated by GTPase-activating 
protein (GAP), coming from another signal transduction pathway. Only the active state of 
the GTPase can transduce a signal to a reaction chain. 
 
The TSC2 contains a leucine zipper in N terminal which is required for the interaction 
with TSC1, and its N terminal is homologous to GAP. TSC2 weakly increase the intrinsic 
GTPase activity of the small GTPase Rap1 and Rab5 (Wienecke, R. 1995) (Xiao, G. 
1997). So suggest that the TSC1/TSC2 heterodimer perform the enzymatic activity, as a 
GAP for a small GTPase. Both human and mouse cells contain Rheb genes, encode the 
small GTPase Rheb (Ras homolog enriched in brain). When Rheb gene is overexpressed 
in mammalian cells, Rheb is primarily in the GTP-bound activated state (Im, E. 2002). 
Rheb promotes S6K activation in a rapamycin-dependent manner. On the other hand, 
other 17 GTPase doesn’t perform the kind of effect (Zhang, Y. 2003) (Castro, A. 2003). 
TSC2 exhibits a selective GAP activity toward Rheb, overexpression of TSC1/TSC2 
heterodimer decreases the GTP-bound Rheb to GDP-bound Rheb (Garami, A. 2003). 
Therefore, Rheb functions downstream of the TSC1/TSC2 heterodimer. TSC2 acts as a 
GAP for Rheb, negatively regulates Rheb activity. 
 
In mammalian cells, overexpression of Rheb increase the activation of mTOR, and 
overexpression of a dominant-negative Rheb inhibits activation of mTOR, as measured 
by S6K1 and 4E-BP1 phosphorylation (Tabancay Jr. 2003). So the Rheb acts as a 
positive regulator on upstream of mTOR, and as a downstream effector of PI3K/Akt. 
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4 Cancer and mTOR 
 
4.1 Cancer 
 
Cancer is a group of diseases in which cells are aggressive (grow and divide without 
respect to normal limits), invasive (invade and destroy adjacent tissues), and/or metastatic 
(spread to other locations in the body). These three malignant properties of cancers 
differentiate them from benign tumors, which are self-limited in their growth and do not 
invade or metastasize. However, some benign tumor types are capable of becoming 
malignant. Cancer may affect people at all age, even fetuses, but risk for the more 
common varieties tends to increase with age. 
 
Nearly all cancers are caused by abnormalities in the genetic material of the transformed 
cells. These abnormalities may be due to the effects of carcinogens, such as tobacco 
smoke, radiation, chemicals, or infectious agents. Other cancer-promoting genetic 
abnormalities may be randomly acquired through errors in DNA replication, or are 
inherited, and thus present in all cells from birth. Complex interactions between 
carcinogens and the host genome may explain why only some cases develop to cancer 
after exposure to a known carcinogen. New aspects of the genetics of cancer pathogenesis, 
such as DNA methylation, and miRNAs, are increasingly being recognized as important. 
 
Cancer is fundamental a disease of regulation of tissue growth. In order for a normal cell 
to transform into a cancer cell, genes which regulate cell growth and differentiation must 
be altered. Genetic changes can occur at many levels, from gain or loss of entire 
chromosomes to a mutation affecting a single DNA nucleotide. There are two broad 
categories of genes which are affected by these changes. Oncogenes may be normal 
genes which are expressed at inappropriately high levels, or altered genes which have 
novel properties. Oncogenes promote cell growth through a variety of ways. Many can 
produce hormones, a “chemical messenger” between cells which encourage mitosis, the 
effect of which depends on the signal transduction of the receiving tissue or cells. In other 
words, when a hormone receptor on a recipient cell is stimulated, the signal is conducted 
from the surface of the cell nucleus to effect some change in gene transcription regulation 
at the nuclear level. Some oncogenes are part of the signal transduction system itself, or 
the signal receptors in cells and tissues themselves, thus controlling the sensitivity to such 
hormones. Oncogenes often produce mitogens, or are involved in transcription of DNA in 
protein synthesis. In either case, expression of these genes promotes the malignant 
phenotype of cancer cells.  
 
Tumor suppressor genes are genes which inhibit cell division, survival, or other 
properties of cancer cells. Tumor suppressor genes are often disabled by 
cancer-promoting genetic change. Tumor suppressor genes often encode for 
anti-proliferation signals and proteins that suppress mitosis and cell growth. Generally, 
tumor suppressors are transcription factors that are activated by cellular stress or DNA 
damage. Often DNA damage will cause the presence of free-floating genetic material as 
well as other signs, and will trigger enzymes and pathways which lead to the activation of 
tumor suppressor genes. The functions of such genes are to arrest the progression of the 
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cell cycle in order to carry out DNA repair, prevent mutations to be passed to daughter 
cells. For example, the p53, one of the most important studied cancer suppressor genes, is 
a transcription factor activated by many cellular stressors, including hypoxia and 
ultraviolet radiation damage. Despite nearly half of all cancers involve alterations in p53, 
its mechanism of tumor suppressor function is poorly understood. p53 clearly has two 
functions, it plays a nuclear role as a transcription factor, and a cytoplasmic role in 
regulation the cell cycle, cell division, and apoptosis. 
 
Cancer can be treated by surgery, chemotherapy, radiation therapy, immunotherapy, 
monoclonal antibody therapy, or other methods. The choice of therapy depends upon the 
location and grade of the tumor and the stage of the disease, as well as the general state of 
the patient. A number of experimental cancer treatments are also under development. 
Complete removal of the cancer without damage to the rest of the body is the goal of 
treatment. Sometimes this can be accomplished by surgery, but the propensity of cancers 
to invade adjacent tissues or to spread to distant sites by microscopic metastatic often 
limits its effectiveness. The effectiveness of chemotherapy is often limited by toxicity to 
other tissues in the body. Radiation can also cause damage to normal tissues. Because 
cancer refers to a class of diseases, it is unlikely that there will be a single “cure for 
cancer”. (The Cell, Alberts et al. 4. ed. 2002) 
 
4.2 mTOR signaling and human cancer 
 
The signaling pathways that regulate mTOR activity are frequently activated in human 
cancers. One mechanism by which mTOR can contribute to cancer development is 
through its effect on cell cycle progression in conjunction with its possible anti-apoptotic 
activity. mTOR is required for cell cycle progression, and inhibition of mTOR activity by 
rapamycin arrests cells in the G1 phase of the cell cycle. Expression of a 
rapamycin-resistant mutant of mTOR reduces the effect of rapamycin on cell cycle 
progression, and there is evidence that the effect of rapamycin on cell cycle progression 
occurs by the inhibition of the downstream effectors of mTOR, S6K, and eIF4E. (Fingar. 
2004) The inhibition of mTOR activity by rapamycin accelerates apoptosis. (Shi. 1995) 
eIF4E inhibits apoptosis in some instances (Polunovsky. 1996). However, the exact 
mechanism by which eIF4E inhibits apoptosis is not clear. 
 
As described above, these components form the eIF4E complex function to recognize the 
mRNA 5’ cap structure and unwind the 5’ secondary structure of the mRNA. Hereby, 
when tight regulation of eIF4E or eIF4G is occurred by mTOR, the translation of mRNAs 
containing such structures would be enhanced and lead to the production of proteins that 
would increase cell growth and proliferation. In addition, S6K1 phosphorylates the 40S 
ribosomal protein S6. The phosphorylation steps lead to the recruitment of the 40S 
ribosomal subunit into actively translating form. In this way, S6K enhances the 
translational capacity of cells. The strong evidences support a role for the ability of 
mTOR to regulate mRNA translation in the genesis of cancer. 
 
Aberrant PI3K-dependent signaling and aberrant protein translation may contribute to the 
development and progression of human cancers. (Table 1) Both activating mutations and 
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amplification of oncogenes and loss of tumor suppressor genes occur within the pathway 
in human cancer disease with high frequency. 
 
 
Target Relevance to human cancer 
Protooncogenes  
PI3K Aberrantly high PI3K activity has been implicated in cell transformation, 
tumor progression and treatment resistance. 
Akt Gastric adenocarcinoma, ovarian, breast, pancreatic cancers. 
eIF4E Aberrant overexpression of eIF4E can transform cells. eIF4E is 
overexpressed in many human tumors. 
S6K1 Amplified or overexpressed in a large fraction of breast and ovarian cancers.
Tumor 
Suppressors 
 
PTEN Brain, bladder, breast, prostate, and endometrial cancer, and glioblastoma. 
TSC1/2 
Complex 
Individuals with mutations in TSC1 or TSC2 develop tuberous sclerosis 
complex (TSC) characterized by the formation. 
 
Table 1. Tumor genes and suppressor genes in the mTOR pathway. (Xiaolin Wan. 2007) 
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5 Rapamycin 
 
 
5.1 The history of rapamycin 
 
The rapamycin, also known as sirolimus, is a natural product of the soil bacterium 
Streptomyces hygroscopicus, found on Easter Island (Rapa Nui), was identified about 30 
years ago during antibiotic screening. (Vezina. 1975) It was initially recognized as an 
antifungal antibiotic. In the 1990s, it was adopted in organ transplantation as an 
immunosuppressive drug, where observed that rapamycin has antitumour property.  
 
5.2 Rapamycin and its derivatives 
 
Rapamycin (Figure. 9) is poor aqueous solubility and chemical stability which limit its 
clinical development as an anti-cancer drug. Several rapamycin analogs that perform 
more favorable pharmaceutical characteristics have been synthesized. The most notable 
of the rapamycin analogs currently in clinical development as anti-cancer agents include 
the cell cycle inhibitor-779 (CCI-779, also known as Temsirolimus) (Figure. 10), RAD 
001 (also known as Everolimus, Novartis Pharmaceuticals, AG, Basel, Switzerland) 
(Figure. 11), and Deforolimus (also known as AP23573, Ariad Pharmaceuticals, 
Cambridge, MA), Ariad initiated deforolimus global Phase 3 clinical trial in September 
2007. 
 
 
 
 
Figure. 9 Structures of rapamycin. X:CH2   Y:CH2   Z:C=O  
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Figure. 10 Structures of Temsirolimus, it’s also known as CCI-779  
 
 
 
 
Figure. 11 Structures of Everolimus, it’s also known as RAD 001.  
 
 
5.3 Mechanism of action of rapamycin and its derivatives 
 
Rapamycin binds to the FK506-binding protein of 12 kDa (FKBP12) and the 
FKBP12-rapamycin complex binds to the FKBP12-rapamycin binding (FRB) domain 
which adjacent to the kinase domain of mTOR. The resulting complex may alter the 
composition and/or conformation of the multi-protein mTOR complexes, and impair 
either upstream signaling leading to mTOR activation, or access to substrates. (Nissim 
Hay. 2004) 
 
The inhibition of mTOR blocks the phosphorylation of 4E-BP1 and the activation of the 
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40S ribosomal protein S6 kinase. The dephosphorylated 4E-BP1 binds tightly to eIF-4E, 
so inhibiting the translation of mRNAs. (See details in section 2.3.1) The blocked 
activation of S6K leads to reduce translation of 5’ TOP mRNAs. (See details in section 
2.3.2) 
 
 
Conclusion 
 
The mTOR PI3K/Akt pathway is as central regulation factor in the etiology of cancer. 
The recently advanced understanding of upstream and downstream targets of mTOR 
explains the origin of the disease on the molecular biology level.  
 
In the PI3K/Akt pathway, PI3k is a positive regulator of mTOR. The effect of inhibition 
or activation on PI3k eventually inhibits the phosphorylation of S6K1 or promotes 
phosphorylation of 4E-BP1. PTEN counteracts the activity of PI3K. The activity of Akt 
sufficiently promotes S6K1 phosphorylation. However, the 4E-BP1 phosphorylation is 
more dependent on Akt activity. TSC1/TES2 heterodimer is an upstream negative 
regulator of mTOR. When overexpression of both TSC1 and TSC2, it decreases 
phosphorylation of S6K1 and 4E-BP1. When lacking a functional TSC1 or TSC2, S6K is 
highly phosphorylated in mammalian cells. The mechanism that Akt regulates 
TSC1/TSC2 function is still unknown. Rheb (positive regulator) increase the activation of 
mTOR, measured by S6K1 and 4E-BP1 phosphorylation.  
 
The main downstream factors (4E-BP1 and S6K1) act the key roles for mTOR in cell 
proliferation. They affect ribosome assembly on mammalian translation and the activity 
of 40S ribosomal subunit respectively. 
 
The relationship between the mTOR pathway and cancer is clearly confirmed, the most 
factors in the pathway are directly implicated in cancer initiation and progression by 
protein synthesis level. The enhanced studies of the signaling pathway should lead to the 
research of the anti-tumor drug development.  
 
As the mTOR inhibitor from natural product, rapamycin is formed with FKBP12. The 
FKBP12-rapamycin complex binds to the mTOR FRB domain. The resulting complex 
may alter the composition and/or conformation of the multi-protein mTOR complexes, 
and impair either upstream signaling leading to mTOR activation, or access to substrates. 
Rapamycin and its water soluble analogs CCI-779, RAD 001, and AP23573 have the 
potent properties of antiproliferation. They widely inhibit the proliferation of a broad 
range of human tumors.  
 
Understanding mTOR and its upstream factors help to invent new anti-tumor medicine 
such as CCI-779, RAD 001, and AP23573. The exciting goal has been progressing, and 
the discoveries have begun to show promising clinical implications. 
 
Although mTOR has been known to control cell proliferation, the roles of specific 
mTOR-dependent pathways have not been completely defined. For example, the deletion 
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of S6K1 in embryonic stem cells does not block the capacity of the cell proliferation, and 
rapamycin treatment further reduces proliferation rate of these cells. (Kawasome. 1998) 
In addition, rapamycin completely inhibits S6K1 and S6K2 activity, only modestly 
reduces total protein synthesis, and only delays cell cycle progression, under some 
specific conditions. (Diane. 2004) These studies indicate the suggestion that other 
mTOR-dependent signaling pathways may contribute to the cell proliferation as well. 
 
S6K1-dependent phosphorylation of ribosomal protein S6 may elevates ribosome 
biogenesis and therefore increase protein synthesis. The mechanism is still unclear.  
 
Rapamycin doesn’t block completely all mTOR signals. As discussed previously, 
mammalian cells conserve two mTOR complexes. One of them, called mTORC2, is 
rapamycin-insensitive. In this case, inhibition of the rapamycin-sensitive functions of 
mTOR by rapamycin treatment would be useful to expose the rapamycin-insensitive 
functions of the mTOR kinase. When develop rapamycin derivatives as anti-cancer drugs, 
the rapamycin-insensitive manner could limit the range of therapy. mTOR signal in 
rapamycin-insensitive manner should be investigated more carefully. 
 
Rapamycin has been confirmed the anti-cancer effects in some specific cancer diseases. 
For example, rapamycin alone results in growth inhibition of sensitive cell lines (not in 
rapamycin-insensitive ones) in breast cancer cells. On the other hand, the effects were 
enhanced by addition other anti-cancer drugs. (Mondesire. 2004) 
 
As the rapamycin derivatives, CCI-779, RAD 001 and AP23573 also should be 
determined that whether they are effective for specific cancer, and the cooperated drugs. 
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